Clinical trials: Psoriasis (PsO)
Psoriasis, Psoriasis (PsO)
Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis
To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary…
- Trial name
- NCT07642544
- Testing
- Standard Maintenance, Non-standard Maintenance
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Psoriasis (PsO)
Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis
To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad
- Trial name
- NCT07635043
- Testing
- Betamethasone Dipropionate 0.05% Cream, Tapinarof Cream 1%
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Pakistan Institute of Medical Sciences
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with…
- Trial name
- BE UNIQUE (NCT06506916)
- Testing
- bimekizumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE BRIGHT (NCT03598790)
- Testing
- Bimekizumab
- Where
- 189 sites in United States, Australia and 11 more
- Volunteers
- 1,353 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
- Trial name
- PsOsim (NCT02489227)
- Testing
- CHS-1420, Adalimumab
- Where
- 99 sites in United States, Bulgaria and 14 more
- Volunteers
- 545 people
- Sponsor
- Coherus Oncology, Inc.
Psoriasis (PsO), Obesity and Overweight
Effect of Semaglutide in Patients With Psoriasis and Obesity
Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics.
- Trial name
- SEMPSO (NCT06937060)
- Testing
- semaglutide
- Where
- Hong Kong
- Volunteers
- 14 people
- Sponsor
- The University of Hong Kong
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
Early diagnosis of psoriatic arthritis (PsA) requires close collaboration between dermatologists (as the skin manifestations of psoriatic disease in most cases precede the musculoskeletal manifestations) and rheumatologists (who…
- Trial name
- COMPOSITION (NCT07298265)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Charite University, Berlin, Germany
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE RADIANT (NCT03536884)
- Testing
- Bimekizumab, Secukinumab
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 743 people
- Sponsor
- UCB Biopharma SRL
Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma…
- Conditions
- Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO), Atopic Dermatitis (AD)
- Trial name
- SKINERGY (NCT07021495)
- Where
- 8 sites in Netherlands
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE SURE (NCT03412747)
- Testing
- Bimekizumab, Adalimumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 478 people
- Sponsor
- UCB Biopharma SRL
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd
Psoriasis (PsO), Psoriasis Arthritis
Molecular Inflammation Board at the Center for Personalized Medicine
Molecular Inflammation Board at the Center for Personalized Medicine
- Conditions
- Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies
- Trial name
- MEB@ZPM (NCT07132333)
- Testing
- Biologic Agent
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Tuebingen
Autoimmune Diseases, Rheumatoid Arthritis (RA)
A Trial of Academic Detailing to Promote Prescribing of Biosimilars
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1.
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)
- Trial name
- NCT07221890
- Testing
- Offered an academic detailing session, Standard-of-care outreach from the insurance plan
- Where
- 2 sites in United States
- Volunteers
- 1,325 people
- Sponsor
- Brigham and Women's Hospital
Psoriatic Arthritis, Psoriasis (PsO)
Inflammation Digital Biomarkers Validation Study
HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease.
- Trial name
- IDBV (NCT07594054)
- Volunteers
- 3,458 people
- Sponsor
- University of Oxford
Psoriasis
PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study
This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO.
- Trial name
- NCT07648602
- Testing
- Observational (Non-Interventional) Registry
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- CorEvitas
Plaque Psoriasis, Psoriasis (PsO)
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: How safe is taking ESK-001 long-term in people with moderate to…
- Conditions
- Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
- Trial name
- ONWARD3 (NCT06846541)
- Testing
- Open-Label Envudeucitinib, Blinded Envudeucitinib
- Where
- 268 sites in United States, Australia and 14 more
- Volunteers
- 1,680 people
- Sponsor
- Alumis Inc
Psoriasis
Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.
- Trial name
- DCE (NCT05065762)
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
- Trial name
- NCT06952465
- Testing
- Deucravacitinib, Any biologic treatment for psoriasis
- Where
- 2 sites in Japan
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis (AD), Psoriasis (PsO)
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug.
- Trial name
- NCT06982352
- Testing
- LPX-TI641
- Where
- 3 sites in United States, Jordan
- Volunteers
- 48 people
- Sponsor
- LAPIX Therapeutics Inc.